April 2017 | Targeted Therapies in Oncology

April 18, 2017

Molecular testing of patients with colorectal cancer should be incorporated into standard practice to establish the mutations each patient has that would affect their response to treatment with EGFR-targeted therapies.

April 18, 2017

Representative Doug Collins (R, Georgia) has proposed a bill that would increase the transparency of payment methodologies to pharmacies.

April 18, 2017

V212, a new inactivated varicella zoster virus vaccine, lowered the cumulative incidence rate of herpes zoster (HZ) infections and HZ-related complications for patients undergoing autologous stem cell transplantation.

April 18, 2017

Experts review the experience of using new and emerging therapies for treating patients with acute and chronic graft-versus-host disease.

April 18, 2017

Responses to treatment with avelumab monotherapy can increase in certain subtypes of patients with metastatic Merkel cell carcinoma, per an analysis of the phase II JAVELIN Merkel 200 trial that was presented during the ASCO-SITC Clinical Immuno-Oncology Symposium.

April 18, 2017

Immunotherapy agents have shown great promise for the treatment of patients with head and neck cancer; however, only a small subset of patients reap these benefits. Thus, the question becomes: which patients are more likely to benefit from these therapies, and why?

April 14, 2017

Patients with hematologic malignancies who receive a hematopoietic stem cell transplant (HSCT) still risk treatment failure through relapse. As part of a conditioning regimen prior to allogenic HSCT, strategies are emerging to improve HSCT outcomes by reducing the risk of relapse. Several of these conditioning regimens were reviewed during a satellite symposium to the 2017 BMT Tandem Meetings.